Werner Wenning, chairman of Germany's Bayer AG, says that 2007 has been the firm's most successful year to date. The company reported that, excluding several special items, its annual earnings before interest, depreciation and amortization grew 21.4% to 6.78 billion euros ($10.23 billion). Revenue for the period increased 11.8% to 32.39 billion euros. In its financial report, the Leverkusen-headquartered company said that it anticipates a further earnings hike in 2008. Full coverage of Bayer's results will appear in next week's Marketletter.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze